

BIOCON GROUP

FACT SHEET

March - 2013

FY 2013 vs. FY 2012
Q4 FY 2013 vs. Q4 FY 2012

BIOCON LIMITED (CONSOLIDATED) AUDITED		
BALANCE SHEET		(Rs. Crores)
	March 31, 2013	March 31, 2012
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,595	2,172
	2,695	2,272
Minority interest	65	4
Non-current liabilities		
(a) Long-term borrowings	164	70
(b) Deferred tax liability (net)	41	-
(c) Other long-term liabilities	424	583
(d) Long-term provisions	4	-
	633	653
Current liabilities		
(a) Short-term borrowings	85	187
(b) Trade payables	346	348
(c) Other current liabilities	346	269
(d) Short-term provisions	246	212
	1,023	1,016
TOTAL	4,416	3,945
ASSETS		
Non-current assets		
(a) Fixed assets	1,810	1,647
(b) Good will	12	12
(c) Non-current investments	65	64
(d) Deferred tax asset (net)	-	8
(e) Long term loans and advances	248	190
(f) Other non-current assets	41	24
	2,176	1,945
Current assets		
(a) Current Investments	522	492
(b) Inventories	398	378
(c) Trade receivables	510	492
(d) Cash and cash equivalents	673	523
(e) Short term loans and advances	81	79
(f) Other current assets	56	36
	2,240	2,000
TOTAL	4,416	3,945

BIOCON LIMITED (CONSOLIDATED)					
PROFIT & LOSS STATEMENT					
<i>(Rs. Crores)</i>					
Particulars	Q4 FY 13	Q3 FY 13	Variance	Q4 FY 12	Variance
INCOME					
Biopharmaceuticals *	380	409	-7%	406	-7%
Branded formulations - India	84	86	-1%	65	30%
Total Biopharmaceuticals	464	495	-6%	471	-2%
Contract research	166	140	19%	118	41%
Total Sales	630	635	-1%	589	7%
Other income	19	25	-26%	33	-43%
Total Revenue	649	660	-2%	622	4%
EXPENDITURE					
Material & Power Costs	310	307	1%	277	12%
Staff costs	99	88	13%	76	30%
Research & Development **	43	43	-	53	-18%
Other Expenses	73	55	32%	61	20%
Manufacturing, staff & other expenses	525	493	7%	466	13%
EBITDA	124	167	-26%	156	-21%
Interest and finance charges	1	3	-69%	3	-70%
Depreciation & Amortisation	46	46	-	43	6%
PBT BEFORE EXCEPTIONAL ITEM	77	118	-35%	110	-30%
Exceptional Item, Net	202	-	-	-	-
PBT	279	118	136%	110	154%
Taxes	28	25	11%	12	134%
NET PROFIT BEFORE MINORITY INTEREST	251	93	170%	98	156%
Minority Interest	2	1		-	
NET PROFIT FOR THE PERIOD	249	92	170%	98	154%
EPS Rs.	12.4	4.6		4.9	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>					
* Biopharmaceuticals Income includes:					
Licensing development fees	-	-		46	
Licensing Income	2	9		-	
** Gross Research & Development expenses	49	49		53	

BIOCON LIMITED (CONSOLIDATED) AUDITED
PROFIT & LOSS STATEMENT (Rs. Crores)

Particulars	FY 13	FY 12	Variance
INCOME			
Biopharmaceuticals *	1,523	1,380	10%
Branded formulations - India	348	259	34%
Total Biopharmaceuticals	1,871	1,639	14%
Contract research	557	410	36%
Total Sales	2,428	2,049	18%
Other income	110	99	11%
Total Revenue	2,538	2,148	18%
EXPENDITURE			
Material & Power Costs	1,187	949	25%
Staff costs	358	287	25%
Research & Development **	164	137	20%
Other Expenses	233	197	18%
Manufacturing, staff & other expenses	1,942	1,570	24%
EBITDA	596	578	3%
Interest and finance charges	8	12	-34%
Depreciation & Amortisation	179	174	3%
	409	392	4%
Exceptional Income, Net	202	-	-
PBT	611	392	56%
Taxes	98	54	81%
NET PROFIT BEFORE MINORITY INTEREST	513	338	52%
Minority Interest	4	-	-
NET PROFIT FOR THE PERIOD	509	338	51%
EPS Rs.	25.5	16.9	
<i>Note: The figures are rounded off to the nearest million, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing development fees	-	125	
Licensing Income	25	1	
** Gross Research Development spends :	198	137	